The KDM4 subfamily H3K9 histone demethylases are epigenetic regulators that control chromatin structure and gene expression by demethylating histone H3K9, H3K36, and H1.4K26. The KDM4 subfamily mainly consists of four proteins (KDM4A-D), all harboring the Jumonji C domain (JmjC) but with differential substrate specificities. KDM4A-C proteins also possess the double PHD and Tudor domains, whereas KDM4D lacks these domains. KDM4 proteins are overexpressed or deregulated in multiple cancers, cardiovascular diseases, and mental retardation and are thus potential therapeutic targets. Despite extensive efforts, however, there are very few KDM4-selective inhibitors. Defining the exact physiological and oncogenic functions of KDM4 demethylase will provide the foundation for the discovery of novel potent inhibitors. In this review, we focus on recent studies highlighting the oncogenic functions of KDM4s and the interplay between KDM4-mediated epigenetic and metabolic pathways in cancer. We also review currently available KDM4 inhibitors and discuss their potential as therapeutic agents for cancer treatment. K E Y W O R D S anticancer agent, epigenetic agent, histone H3K9 demethylase, KDM4, KDM4 inhibitor 3462 | LEE Et aL.
| INTRODUCTION
Epigenetics refers to the stable inheritance of phenotype from alterations in chromosomes without changes in the DNA sequence. Major epigenetic mechanisms include DNA methylation and reversible histone covalent modifications such as acetylation, methylation, and ubiquitination, chemical changes that alter the accessibility of genes to transcriptional pathways. 1 Among histone modifications, histone methylation is strongly linked to tumorigenesis and cancer chemoresistance. Histone methylation is mediated by histone lysine methyltransferases (KMTs) and histone arginine methyltransferases (PRMTs) that catalyze the transfer of methyl groups from S-adenosyl-methionine to lysine (K) and arginine (R), respectively, and reversed by histone lysine demethylases (KDMs) and histone arginine demethylases. 2 More than 30 members of the KDM family have been identified. These KDMs are grouped into six subfamilies | 3463 LEE Et aL. vary depending on the subtype of KDM4s. KDM4 catalyzes the demethylation of di-and tri-methylated histone H3 lysine 9 (H3K9me2/me3) 10 (Figure 2 ), while some KDM4s can also weakly demethylate H3K36me3 and H1.4K26me3 in vitro. 2, 9 In addition, some KDM4s can demethylate H3K27me2/3. 11 Enzymes KDM4A-C are more efficient at demethylating H3K9me3/H3K36me3 than H3K9me2/H3K36me2, whereas KDM4D is more efficient at H3K9me2 than H3K9me3. Through these specific activities, KDM4 stimulates or represses the expression of specific target genes. Heterochromatin regions that are condensed and transcriptionally silent are generally enriched in H3K9me, and loss or reduction of H3K9me3 causes this facultative heterochromatin to decondense and become transcriptionally permissive. Therefore, overexpression of KDM4 can lead to the downregulation of H3K9me3 and aberrant gene activation.
KDM4 proteins are overexpressed in cardiovascular diseases, mental retardation, and multiple cancers, 12 including breast cancer, prostate cancer, and lymphomas, and thus have emerged as potential broad-spectrum therapeutic targets. 13 Deregulation of KDM has been associated with (i) chromosomal stability change, (ii) tumor suppressor silencing, (iii) oncogene activation, and (iv) hormone receptor binding and downstream signaling. Different KDMs may have distinct oncogenic functions based on their cellular localization. For instance, despite high sequence homology, KDM4A-C exhibit unique subcellular distributions in cancer cells, with KDM4A expressed at comparable levels in both the nucleus and cytoplasm, KDM4B expressed at higher levels in the nucleus, and KDM4C more associated with chromatin.
While single knockout (KO) mice for Kdm4a-Kdm4d and double knockout mice for Kdm4a/Kdm4b and Kdm4b/ Kdm4c are viable, Kdm4a/Kdm4c double-and Kdm4a/ Kdm4b/Kdm4c triple-knockout mice are embryonic lethal, suggesting functional redundancy within the KDM4 family. [14] [15] [16] [17] Kdm4a/Kdm4b/Kdm4c triple-knockout perturb the progression of acute myeloid leukemia (AML) in mice, whereas Kdm4c single knockout does not have any effect, indicating that KDM4 catalytic activity is required for the survival of AML cells. 14 Knockdown of KDM4B, KDM4C, and KDM4D in xenograft mice inhibits the proliferation of breast cancer, 18 AML, 19 and colorectal cancer (CRC) cells, 17 respectively. Also, Kdm4d knockout mice develop fewer colitis-associated colorectal tumors than controls. Thus, each of these KDM4 proteins may perform distinct functions as well as overlapping functions, including tumorigenesis.
Indeed, there is mounting evidence that KDM4A-C are directly involved in tumorigenesis and as such may be promising targets for novel anticancer epigenetic agents. Several small-molecule KDM4 inhibitors have been identified, which fall into four classes according to the inhibitory mechanism: α-KG or 2-OG cofactor mimics, metal cofactor disruptors, histone substrate competitive inhibitor, and substrate-and cofactor-independent inhibitors. However, studies on the mechanisms and antitumor activities of KDM4 inhibitors are limited. Due to the structural similarity of KDMs and the conserved properties of the active site, selectivity and specificity are major challenges to the development of KDM4 inhibitors. To overcome these challenges, novel inhibitors targeting alternative sites have also been investigated.
This review focuses on recent studies on the potential oncogenic functions of KDM4 subfamily enzymes and the link between metabolism and KDM4 in cancer and summarizes current knowledge on KDM4-selective inhibitors as therapeutic agents for cancer treatment.
| ALTERED EXPRESSION AND

FUNCTIONS OF KDM4S IN CANCER
Numerous studies have demonstrated that abnormal expression of KMTs and KDMs can promote the progression of cancer, including multiple reports that KDM4A, KDM4B, and KDM4C are amplified and overexpressed in breast, esophageal, lung, prostate cancers, and lymphatic cancers among other cancer types. 12, [20] [21] [22] [23] [24] Some of these studies are summarized in Table 1 . The cancer genome atlas (TCGA) dataset has also revealed significant amplification of KDM4C genomic regions in human cancer cells. 25 
| KDM4A
KDM4A demethylates H3K9me2/me3, weakly demethylates H3K36me3 (at a 5-fold lower rate than H3K9me2/me3), 10 and more specifically demethylates H1.4K26me3 than other subtypes in vitro. 9 In addition to gene activation via chromatin decondensation, KDM4A represses gene expression through association with histone deacetylases (HDACs) 26, 27 and transcription factors such as p53. 26 The crystal structure of KDM4A indicates that JmjN and JmjC domains bind to each other 4 and to the histone substrate, 28 suggesting that both domains are required for catalysis. 29, 30 Based on the phylogenetic analysis, KDM4A and KDM4C are structurally and functionally more similar to each other than to either KDM4B or KDM4D. 2 The expression levels of KDM4A and KDM4B, but not KDM4C or KDM4D, are controlled from the E3 ubiquitin ligases RNF8 and RNF168 complexes in response to DNA damage. 31 KDM4A amplification and overexpression is highly prevalent in ovarian cancer and squamous cell carcinoma (SCC). 20, 32 The involvement of KDM4A proteins has also been demonstrated in various cancers: prostate, breast, lung, colon, bladder, pancreatic, gastric, head and neck cancers, endometrial carcinoma, and glioblastoma, etc. 
| Prostate cancer (PCa)
Androgens receptor (AR) signaling is a crucial driver of prostate cancer (PCa) progression 33 and KDM4A-D act as AR coactivators. 9, 34, 35 Moreover, KDM4A-C is overexpressed in prostate tumors and PCa cell lines. 10 Alternatively, no KDM4 mutations have been linked to PCa. 36 Expression of KDM4A mRNA is only slightly elevated in PCa compared to benign prostatic hyperplasia (BPH), while KDM4C expression is significantly higher in castration-resistant PCa (CRPC) than in untreated PCa or BPH. KDM4A activates the prostate-specific antigen (PSA) gene by stimulating AR, forming a complex with AR, and by demethylating H3K9me3 at the PSA promoter. 34, 37 KDM4A also directly promotes androgen-dependent PCa cell proliferation. The leucine-rich repeat domain-containing G-protein-coupled receptor 4 (GPCR4 or Lgr4) induces KDM4 activation and interaction with AR, which reduces cell apoptosis and maintains the cell cycle in S phase. 38 In addition to AR, KDM4A binds to the ETS transcription factor ETV1, which recruits KDM4A to the yes-associated protein 1 (YAP1) gene promoter and increases YAP1 expression. 39 As a part of the Hippo signaling pathway, YAP1 is a downstream effector of KDM4A associated with prostate tumor progression. Exogenous KDM4A overexpression also promotes PCa in mice. 39 Similar to ETV1, the oncogenic ERG cooperates with KDM4A and induces PCa by activating the YAP1 promoter. 40 Alternatively, the microRNAs has-miR-137 (miR137) and miR10a are direct negative regulators of KDM4A in PCa cells. The inhibition of miR137 functionally enhances the androgen induction of PSA expression. 41 Conversely, MiR-10a can function as a tumor suppressor in PCa by negatively regulating KDM4A and the downstream Hippo-YAP1 pathway. 42
| Breast cancer
KDM4A is overexpressed at both mRNA and protein levels (~60%) in breast cancers, 43 with distinct expression profiles among individual breast tumor types. For instance, KDM4A and KDM4D are predominant forms overexpressed in basal breast cancer, while KDM4A expression is higher in infiltrating duct carcinoma than fibroadenoma 44 and KDM4B overexpression is predominant in both estrogen receptor (ER)-positive breast cancer 45 and triple-negative breast cancer. 46 In infiltrating duct carcinoma, KDM4A expression is negatively correlated with ADP-ribosylarginine hydrolase 1 (ARH1) expression and positively correlated with p53 and ER expression. Overexpression of KDM4A contributes to breast carcinogenesis by stimulating ERα activity, in part by forming a complex with ERα and promoting ERα-mediated transcription. 47 Alternatively, KDM4A downregulation reduces the expression of c-Jun and cyclin D1, two prominent ERα target genes in T47D breast cancer cells, thereby inhibiting cancer cell growth.
The KDM4A expression level is also associated with tumor grade, TNM stage, histological type, and disease-free survival (DFS). 48 KDM4A inhibits the autoregulation of Sp1 and Sp1 expression is negatively correlated with the TNM stage and metastasis status. Sp1 negatively controls breast cancer metastasis by the transcriptional activation of ARHI, and ARHI expression is negatively correlated with KDM4A expression. 49 Consistent with these associations, knockdown of KDM4A can inhibit the proliferation, migration, and invasion of the breast cancer cell line MCF-7. 50 Hypoxia causes transient site-specific copy gains (TSSGs) in primary, non-transformed, and transformed human cells. 51 These hypoxia-driven TSSGs are independent of hypoxiainducible factor-1α (HIF-1α) and HIF-2α and are prevented by KDM4A inhibition with succinate. KDM4A expression is controlled by hsa-mir-23a-3p, hsa-mir-23b-3p, and hsamir-137, and manipulating the expression of these miRNAs alters KDM4A-mediated TSSG. Specifically, miRNA inhibition promotes TSSGs and increases the expression of the known drug-resistance gene CKS1B in primary breast tumors 50 and decreases the cisplatin sensitivity of breast cancer cells.
| Lung cancer
A study of 188 patients with lung carcinoma implicated nuclear KDM4A and KDM4D in lymph node metastases. 52 In addition, the cytoplasmic KDM4A expression level was positively correlated with both shorter overall survival and recurrence-free interval. KDM4A is overexpressed in human and mouse lung cancer cell lines, while KDM4A knockdown inhibits tumor growth and prompts the apoptosis of non-small cell lung cancer (NSCLC) cells. 53 This effect of KDM4A on NSCLC cell growth is dependent on miR-150, which is upregulated in NSCLC cells and downregulated by KDM4A knockdown, suggesting that miR-150 is an endogenous feedback regulator of KDM4A expression. Indeed, miR-150-mediated silencing of KDM4A is attenuated by the inhibition of cell proliferation.
KDM4A directly upregulates the expression of tumorassociated genes, including ADAM12, CXCL5, and JAG1, through the modulation of H3K9 methylation. 54 ADAM12 facilitates tumor cell growth by the proteolytic cleavage of epithelial growth factor receptor (EGFR) ligands. 55, 56 CXCL5 implicated in the promotion of tumor growth and angiogenesis. 57 JAG1 enhances cell proliferation by acting as a ligand in the canonical notch signaling pathway. 58 KDM4A also acts as a negative regulator of Ras-induced senescence and promotes cell transformation by negatively controlling the p53 pathway in cooperation with carcinogenic Ras. 59 KDM4A inhibition induces the expression of the tumor-suppressing chromodomain helicase DNA-binding protein 5 (CHD5) and downregulates the p53 pathway. KDM4A inhibition also markedly suppresses BrdU incorporation and proliferation of lung cancer cells. The deacetylase sirtuin 2 (SIRT2) is downregulated in NSCLC, 60 while SIRT2 upregulation inhibits NSCLC cell proliferation, colony formation, and tumor growth in vitro and in vivo. These effects are KDM4A-dependent as SIRT2 binds to the promoter region of KDM4A and negatively regulates KDM4A expression in NSCLC. North American NSCLC patients homozygous for the KDM4A single nucleotide polymorphism (SNP)-A482 (rs586339) have significantly lower overall survival (OS) than patients harboring the wild-type allele. 61 In addition, mTOR inhibitors reduce KDN4A SNP-A482 protein expression and concomitantly increase anticancer drug sensitivity. 62 However, KDM4A SNP-A482 has no significant effect on OS in Asian NSCLC patients.
These results indicate that KDM4A may play a dual role in lung tumorigenesis by upregulating tumor survival-related genes 55 and by downregulating tumor suppressor genes. 59
| Colorectal cancer (CRC)
KDM4A, KDM4B, and KDM4C are all overexpressed in colon cancer cell lines. 63 Despite high homology, KDM4A-C demonstrate distinct intracellular localization in colon cancer cells, with KDM4A expressed at comparable levels in the cytoplasm and nucleus, and KDM4B is more prevalent in the nucleus.
The depletion of KDM4A reduces CRC cell proliferation, blocks entry into the G2-M phase of the cell cycle, and increases apoptosis. KDM4A is recruited with p53 to the promoter of cell cycle inhibitor p21 in response to DNA damage induced by adriamycin, 64 where it contributes to p21 suppression. Conversely, downregulation of KDM4A increases the expression of p21 and pro-apoptotic puma protein and decreases the expression of antiapoptotic Bcl-2 protein.
The tumorigenic actions of KDM4A are associated with independent enzymatic function in the DNA damage pathway. The Tudor domains of KDM4A and 53BP1 both bind competitively to H4K20me2. Upon DNA damage, ubiquitination mediated by the E3 ubiquitin ligases RNF8 and RNF168 target KDM4A for degradation, which allows 53BP1 recruitment to the DNA damage site, and subsequent initiation of DNA repair. 31 Thus, KDM4A overexpression may hinder DNA damage repair and cause genomic instability by repressing 53BP1 recruitment to DNA damage foci, thus promoting tumorigenesis.
| Pancreatic cancer
In Ras-induced senescence, miR-137 targets and reduces KDM4A mRNA expression. Decreased levels of KDM4A expression results in the activation of the tumor suppressor p53 and retinoblastoma (pRb) pathways. 65 Restoration of KDM4A contributes to the circumvention of miR-137induced senescence, and inhibition of endogenous miR-137 by a miRNA sponge-compromises Ras-induced senescence. However, the miR-137 expression is substantially lower in pancreatic tumors. In contrast, the recovery of miR-137 expression inhibits proliferation and promotes the senescence of pancreatic cancer cells. These findings suggest that the KDM4A-miR-137 axis is a promising therapeutic target for the treatment of pancreatic cancer.
| Gastric cancer
KDM4A is overexpressed in clinical gastric cancer tissues compared to normal gastric mucosa. 66 Moreover, KDM4A expression is associated with tumor stage and nodal status, and higher expression predicts poor OS and disease-free survival (DFS). KDM4A knockdown induces apoptosis by upregulating pro-apoptotic proteins and downregulating antiapoptotic proteins. In addition, KDM4A suppresses the expression of pro-apoptotic miR-34a. These results suggest that KDM4A regulates gastric cancer growth and that KDM4A may be a potential therapeutic target for gastric cancer treatment.
| Endometrial carcinoma (EC)
KDM4A is overexpressed in endometrial cancer. 64, 67 Downregulation of KDM4A reduces the proliferation, invasion, and metastasis of endometrial cancer lines RL95-2 and ISK. Expression levels of KDM4A and AR expression are positively correlated in EC cell lines with low baseline AR expression, whereas KDM4B and AR are positively correlated in high AR-expressing cell lines. 67 In AN3CA cells with low AR expression, KDM4A inhibits the AR signaling cascade and promotes EC progression. KDM4A and AR downregulate expression cell cycle regulator p27 by H3K4me3 demethylation of the p27 promoter, while KDM4B and AR upregulate expression of the oncogene c-MYC. Patients with changes in AR, KDM4A, KDM4B, and c-MYC have poor OS and DFS. Thus, KDM4A and KDM4B appear to facilitate EC progression by modulating AR, c-MYC, and p27 activities.
| Glioblastoma
KDM4A expression is high in glioma cell lines U87 and T98G, 68 while KDM4A silencing reduces cell viability, inhibits invasion, and promotes the apoptosis of these cells. A small interfering RNA targeting KDM4A (siKDM4A) | 3467
induces a significant increase in acidic vaginal organelles and upregulates the expression of the autophagy-related proteins, including LC3B-II/LC3B-I and Beclin. Further, the selective inhibition of KDM4A efficiently suppresses glioblastoma cell survival by enhancing autophagy.
| Bladder cancer
The expression of KDM4A is higher in bladder cancer tissues than in corresponding non-neoplastic tissues, but substantial differences in expression have not been reported among different tumor grades. 55 KDM4A and AR expression levels are significantly lower in malignant vs benign urothelium, whereas levels of histone H3K4 demethylase LSD1/KDM1A are higher in the malignant urothelium. 69 Significant reductions in KDM4, KDM1A, and AR are observed during bladder cancer progression, including muscle involvement, hypertrophy, and lymph node metastasis, and lower KDM4A level is associated with poor prognostic features and worse OS. As mentioned, KDM4A directly activates the expression of tumor-associated genes (eg, ADAM12) and AR-induced genes through the modulation of H3K9 methylation. 55 Conversely, KDM4A inhibition markedly suppresses bladder cancer cell growth.
| Head and neck squamous cell carcinoma (HNSCC)
KDM4A induces the binding of the transcription factor activating protein 1 (AP1) complex to promoters of JUN and FOSL1, facilitating a positive feedback loop that maintains the activation of AP1, invasive growth, and metastasis. 32 KDM4A expression is positively associated with lymph node metastasis as well as JUN and FOSL1 expression levels in human HNSCC tissues. This founding suggests that KDM4A inhibition may block invasive HNSCC growth and metastasis.
| KDM4B
KDM4B and KDM4C are not only structurally similar to KDM4A but also show similar target specificities and enzymatic activities in vitro. 9,70 KDM4B and KDM4C demethylate both H3K9 and H3K36. Despite the structural and functional similarity, however, they have different physiological functions and make distinct contributions to tumorigenesis. Whereas KDM4B is active as a monomer and KDM4A, KDM4C, and KDM4D are active as homodimers or heterodimers. 34, 71 KDM4B is specifically induced by binding HIF-1α to the KDM4B promoter and then contributes to the upregulation of hypoxia-inducible genes, which may promote tumor cell survival in a hypoxic tumor environment. [72] [73] [74] [75] [76] Hypoxia is expected to reduce KDM4B function because KDM4B uses O 2 and 2-OG as substrates. 72 This suggests that HIF-1α induces KDM4B expression as a compensatory response for decreased catalytic activity. 75 However, whether the KDM oxygenase cycle is actually inhibited under hypoxia has not been determined. KDM4B is amplified and overexpressed in breast cancer, prostate cancer, and medulloblastoma. 77, 78 Moreover, overexpression is required for proliferation and invasion of colorectal, gastric, pancreatic, and lung cancers. 76, 79, 80 KDM4B overexpression is implicated in liver cancer, ovarian cancers, and osteosarcoma, neuroblastoma, multiple myeloma, and Hodgkin's lymphoma.
| Prostate cancer
Like KDM4A, KDM4B is strongly implicated in the carcinogenesis and progression of PCa and indeed, is the most strongly expressed in PCa among KDM4s. 35, 36, 81 In MFE296 PCa cells with high AR expression, KDM4B activates AR signaling cascade and AR-related genes (eg, PSA) and promotes oncogenic progression. 67 Specifically, KDM4B and AR recruit cisregulatory elements of AR, activate c-MYC, and promote tumor growth by H3K9me3 demethylation. In addition, KDM4B stabilizes AR by inhibiting its ubiquitination and degradation. 22 KDM4B also activates the transcription of Polo-like kinase 1 (PLK1) by interacting with the oncoprotein BMYB in PC3 cells, a cell line derived from PCa bone metastasis lacking AR expression. 35 Moreover, KDM4B expression in clinical PCa specimens is positively correlated with higher cancer grade.
Treatment of LNCaP cells with HDAC inhibitor, trichostatin A (TSA), downregulates KDM4B as well as the expression of the antiapoptotic protein survivin. 82, 83 The TSA-mediated reduction in survivin expression is due, in part, to the KDM4B-mediated modulation of cyclin B1dependent survivin degradation.
| Breast cancer
KDM4B overexpression contributes to tumorigenesis in ERα-positive breast cancer. 45 KDM4B is highly expressed in breast tumors with a chromosomal instability (CIN) phenotype. Overexpression of KDM4B in cultured breast epithelial cells reduces centromere-associated H3K9me3 and increases CIN. 46 Like KDM4A, KDM4B forms a complex with ERα and increases the transcription of ER target genes. 84 KDM4B also forms a complex with mixed-lineage leukemia (MLL)2 H3K4-specific methyltransferase KMT2D. 85 The transcriptional activity of ERα is increased via direct interaction with KDM4B/KDMT2D complex. Depletion of KDM4B in ERpositive MCF7 or T47D cells, but not ER-negative cells, diminishes estrogen-induced G1/S transition, reduces cell proliferation in vitro and inhibits the formation of breast tumors in vivo. 14, 74, 85 The knockdown of KDM4B also inhibits the expression of ERα target genes and stabilizes p53, which blocks breast tumor cell proliferation. Notably, KDM4B is also an ERα target gene and contributes to a feed-forward regulation loop of the estrogen response.
The ER and glucocorticoid receptor form a complex that coactivates to increase the expression of KDM4B and vitamin D receptor. Collectively, effects on gene expression serve to inhibit Wnt signaling. 86 KDM4B expression is also induced by 17-beta-estradiol (E2) in an ERα-dependent manner. 14 Moreover, KDM4B is a direct target of miR-491-5p and ectopic overexpression of KDM4B abolishes miR-491-5p-induced phenotypic changes in breast cancer cells. 87 miR-491-5p is generally downregulated and hypermethylated in ERα-positive breast cancer tissues and cell lines. In contrast, MiR-491-5p overexpression inhibits estrogen signaling and estrogen-stimulated proliferation of breast cancer cells. Thus, miR-491-5p may act as a tumor suppressor in breast cancer progression and so provides a new therapeutic target for ERα-positive breast cancer treatment.
| Lung cancer
KDM4B may also contribute to the pathogenesis of lung cancer cells. In a study of 188 patients with lung carcinomas, KDM4B was not significantly associated with lymph node metastases. 53 However, among 78 patients with resected adenocarcinoma, 50 patients (64%) exhibited KDM4B immunopositivity. 88 The OS of the KDM4Bpositive patients after surgery was significantly lower than that of the KDM4B-negative patients and multivariate analysis identified KDM4B positivity is an independent prognostic factor.
| Colorectal cancer
KDM4B is overexpressed in both CRC cell lines and CRC patients, where overexpression is positively associated with lymph node metastasis. KDM4B expression is also associated with increased CRC tumor invasion, 89 while KDM4B silencing induces CRC cell apoptosis through mitochondriarelated and death receptor-related pathways. Such pathways reduced in the expression of the antiapoptotic Bcl-2 gene family, leads to the translocation of Bak and Bax proteins and mitochondrial membrane potential disruption, and caspase-3-dependent apoptosis. 90 The antiapoptotic protein HAX1 is overexpressed in CRC and required for the KDM4Bmediated suppression of mitochondrial apoptosis. KDM4B directly activates the transcription of HAX1 91 and KMD4B expression is positively correlated with HAX1 expression in CRC tissues.
KDM4B forms a complex with the multifunction Wntassociated protein β-catenin in vivo and in vivo. 92 KDM4B also interacts with the DNA-binding protein transcription factor 4 (TCF4), a major factor promoting β-catenin recruitment to chromatin. Downregulation of KDM4B reduces the expression of the β-catenin/TCF4 target oncogenes JUN, MYC, and CCND1. These results suggest that KDM4B overexpression contributes to CRC tumorigenesis by facilitating β-catenin-mediated gene expression.
KDM4B is also associated with the repair of double-strand breaks (DSBs). 93 Expression of cyclin-dependent kinase 6 (CDK6), an important kinase for G1/S transition, is directly governed by KDM4B, and expression levels of KDM4B and CDK6 are significantly correlated in various cancer cell types. KDM4B is a p53-inducible target gene of the DNA damage response 94 and KDM4B induction attenuates the transcription of key p53 targets genes including p21, PIG3, and PUMA, effects that are dependent on KDM4B catalytic activity. Conversely, depletion of KDM4B delays the repair of heterochromatin DNA and reduces clonogenic survival. 95 KDM4B silencing also enhances the DNA-damage driven induction of p21 and PIG3. KDM4B acts in an autoregulatory loop in which p53 influences its own transcriptional program through KDM4B activation. In addition, KDM4B knockdown induces DNA damage through the activation of the ataxia telangiectasia-mutated (ATM) and Rad3related (ATR) pathway under both normoxia and hypoxia. 96 KDM4B silencing suppresses signal transducers and activators of transcription 3 (STAT3), enhances DNA damage, and sensitizes CRC cells to irradiation. KMD4B is also a target of the cAMP-responsive element-binding protein (CREB) transcription factor in CRC cells. 97 These findings indicate that the CREB-KDM4B-STAT3 signaling axis may be important in the DNA damage response and a novel therapeutic target for CRC radiotherapy.
Recently, it was reported that KDM4B contributes to the mitigation of metastatic stress in CRC cells. KDM4B is upregulated via ERK phosphorylation (p-ERK) during glucose deprivation in CRC cells. 98 Glucose deprivation increases the interaction between KDM4B and p-ERK, resulting in increased KDM4B phosphorylation and stability. The knockdown of KDM4B significantly decreases CRC cell viability and reduces glucose uptake and lactate production by downregulating GLUT1 expression. Further, KDM4B, p-ERK, and GLUT1 expression levels were positively correlated in 85 human CRC tissue samples. These data suggest that ERK-mediated phosphorylation and stabilization of KDM4B during glucose deprivation may sustain in glucose uptake and cancer cell viability under metabolic stress. | 3469 LEE Et aL.
| Pancreatic cancer
KDM4B facilitates cell migration, invasion, and epithelialmesenchymal transition (EMT) in pancreatic cancer. 99 KDM4B epigenetically regulates the expression of the transcription factor ZEB1 during TGF-β-induced EMT and the expression levels of KDM4B and ZEB1 are positively correlated in pancreatic tumor tissues. This finding suggests that KDM4B may be an important factor in EMT and provides a significant potential prognostic marker and therapeutic target for metastatic pancreatic cancer.
| Gastric cancer
KDM4B is overexpressed in gastric cancer tissues compared to the adjacent normal tissues and contributes to gastric carcinogenesis. 80 ,100 KDM4B knockdown markedly suppresses tumor proliferation and xenograft tumor growth in vivo, 80 while KDM4B inhibition by targeted siRNA or miR-491-5p reduces the migration and invasion of gastric cancer cells in vitro 100 and metastasis in vivo. 101, 102 In addition, inhibition of KDM4B prevents the EMT of gastric cancer cells, whereas ectopic overexpression of KDM4B induces EMT. The expression level of KDM4B is also positively correlated with TNM stage, tumor differentiation status, tumor size, tumor invasion, lymph node metastasis, and distant metastasis in gastric cancer patients KDM4B expression is induced via the β-catenin signaling pathway and contributes to the regulation of other downstream target genes through physical association with β-catenin. 101 KDM4B binds to the promoter of β-catenin target genes and increase its transcription via H3K9 demethylation. KDM4B also upregulates miR-125b expression and activates the Wnt signaling pathway. 102 After Helicobacter pylori infection, KDM4B induced by the β-catenin pathway along with nuclear factor-κB (NF-κB) binds to the cyclooxygenase-2 (COX-2) promoter to COX2 transcription. 103 Expression levels of KDM4B and COX-2 gradually increase in human gastric tissues during progression from infection-related gastritis to gastric cancer. Furthermore, KDM4B expression is positively correlated with COX-2 expression in both gastritis and gastric cancer tissues. In addition to NF-κB and β-catenin, KDM4B physically interacts with c-Jun and acts as a coactivator at the IL-8, MMP1, and ITGAV promoters via demethylation activity. KDM4B also upregulates IL-8 production in the absence or presence of H. pylori. 104 Conversely, KDM4B knockdown decreases integrin αV, which is used by H. pylori possessing the type IV secretion system, for the translocation of the virulence factor CagA into gastric cells, thereby reducing IL-8 production and cell migration. KDM4B overexpression is positively correlated with the p-c-Jun abundance in gastric cancer and associated with poor clinical outcomes.
Conversely, KDM4B knockdown induces apoptosis and elevates the expression of p53 and p21 antitumor proteins through the DNA damage response (DDR) pathway in gastric cancer cells and other cancer cells. 80 KDM4B expression is also highly upregulated in gastric cancer by hypoxia and radiation. 105 KDM4B binds to the cyclin A1 (CCNA1) promoter and upregulates CCNA1 under hypoxia. In addition, KDM4B and cyclin A1 expression directly influence AGS gastric cell proliferation. The effects of KDM4B on cell growth under hypoxia are dramatically inhibited by gamma-ray irradiation. These findings suggest that KDM4B inhibition is not only a potential therapeutic target for reducing gastric carcinogenesis but can also mitigate hypoxia-induced radioresistance.
| Osteosarcoma
KDM4B and KDM4C are overexpressed in osteosarcoma tissues compared to adjacent non-tumor tissues. 106 Fibroblast growth factor 2 (FGF2) is upregulated by KDM4B and KDM4C in osteosarcoma cells, and upregulation promotes osteosarcoma cell proliferation, migration, and invasion. Thus, high levels of KDM4B and KDM4C may promote the metastasis of osteosarcoma cells through the upregulation of FGF2.
| Liver cancer
The KDM4B protein level is upregulated in human hepatocellular cancer (HCC) 107 and expression is correlated with histological grade and TNM stage. The hepatitis B virus X protein HBx promotes H3K9 trimethylation at the p16 promoter by downregulating KDM4B expression, which represses p16 gene expression and triggers hepatocarcinogenesis. 108 The H3K9me3 level is substantially higher in HBx-positive HCC tissues than HBx-negative HCC tissues, suggesting deficient KDM4B activity. KDM4B deficiency also causes the CpG methylation of the miR-615-5p promoter and decreases miR-615-5p expression, 109 and this low miR-615-5p expression increases the expression of oncogenic Ras-related protein RAB24 and promotes the growth and metastasis of HCC in vivo and in vivo. Furthermore, the downregulation of miR-615-5p and upregulation of RAB24 promote EMT adhesion and vasculogenic mimicry of HCC cells. Thus, interfering with KDM4B-mediated silencing of miRNA-615-5p and ensuing RAB24 upregulation is a potential strategy to inhibit hepatocarcinogenesis and metastasis.
| Ovarian cancer
Expression of KDM4B also positively correlated with the expression of carbonic anhydrase (CA)-IX, a protein induced when epithelial ovarian carcinoma cell lines are exposed to hypoxic conditions. 110 The depletion of KDM4B increases H3K9me3 at the promoters of metastatic genes such as LOXL2, LCN2, and PDGFB, thereby reducing expression. KDM4B inhibition also suppresses ovarian cancer cell migration, invasion, and spheroid formation in vitro. In addition, hypoxia-inducible KDM4B regulates the growth of peritoneal tumors in vivo.
| Neuroblastoma
KDM4B and MYCN expression levels are significantly correlated in neuroblastoma cells through mutual regulation by the MYC pathway. 111 N-NYC protein (encoded by the MYCN gene) promotes mitochondrial oxidative phosphorylation. In addition, it physically interacts with and recruits KDM4B to regulate neuroblastoma cell proliferation and differentiation in vitro as well as xenograft growth in vivo. Ciclopirox, an approved small-molecule antifungal, inhibits several KDMs, including KDM4B, 112 which in turn reduces MYC function. Thus, ciclopirox inhibits MYC signaling and mitochondrial oxidative phosphorylation, thereby inhibiting neuroblastoma cell viability and tumor growth associated with differentiation. This result suggests that targeting KDM4B as an indirect MYC-targeting approach is promising cancer therapy.
| Hodgkin's lymphoma (HL)
Overexpression of cytoplasmic KDM4B and KDM4D in reactive cellular infiltration and Reed-Sternberg (RS) cells is related to poor DFS in patients with limited-stage HL. 111 KDM4B expression is also associated with B-symptoms and oncogenic progression stages of RS cells. Therefore, KDM4B expression is associated with aggressive subtypes of classical HL and with radioresistance. 113 
| Multiple myeloma (MM)
Triptolide, an extract from Tripterygium wilfordii, 114 has multiple pharmacological actions, including anti-inflammatory, immunosuppressive, antiangiogenic, and anticancer effects, and promotes reversal of drug resistance. [115] [116] [117] [118] Triptolide strongly suppresses the growth of human MM cells through the modulation of KDM4B and KDM1A/LSD1 activities. 119 Triptolide increases histone H3K4me2, H3K9me2, and H3K36me2 levels and induces G0/G1 cell cycle arrest and apoptosis partly by directly downregulating KDM4B and KDM1A expression.
| KDM4C
Emerging evidence also implicates KDM4C in malignant transformation. Amplification of the 9p24 chromosomal region containing the KDM4C and tyrosine kinase JAK2 loci has been observed in primary mediastinal B-cell lymphoma, HL, 120 esophageal squamous cell carcinoma (ESCC), 21 breast cancer, 24 sarcomatoid carcinoma of the lung, 23 and desmoplastic medulloblastoma. 121 One potential oncogenic mechanism of KDM4C overexpression is the delocalization of transcriptional regulator heterochromatin protein 1 (HP1) from target gene promoters, such a c-MYC oncogene, thereby activating oncogenes and increasing genomic instability due to the reduction of H3K9me3 levels and loss of heterochromatin. The binding of HP1 to H3K9me3 on the c-MYC promoter is inhibited by KDM4C-mediated demethylation as well as by JAK-mediated phosphorylation of H3Y41. Alternatively, combined inhibition of KDM4C and JAK2 synergistically promotes the cell death of primary mediastinal B-cell lymphoma and HL cells. 120 The depletion of KDM4C also inhibits the cell growth of many cancers whereas the overexpression of KDM4C in non-transformed epithelial cells results in transformation. Although these findings support KDM4C as an oncogene, it is still controversial whether its overexpression is a cause or effect of tumorigenesis. However, due to genomic amplification in cancer cells and various oncogenic properties, KDM4C is mainly regarded as an oncogene and thus a potential target for antitumor epigenetic drugs. 122 KDM4C is deregulated in several other cancer types including prostate, breast, lung and colon cancer, osteosarcoma, ESCC, acute myeloid leukemia, and lymphoma.
| Prostate cancer
Oxygen concentration is significantly lower in PCa tissue than non-cancerous prostate tissue. 123 Like KDM4A, KDM4C is inhibited by oxygen deprivation. However, KDM4C is also required for PCa cell proliferation, 10 and its expression is higher in CRPC, compared to hormone-sensitive tumors and BPH, 36 possibly as a compensatory response to lower activity. In combination with LSD1/KDM1A, KDM4C binds to the AR in vitro and in vivo, and the complex cooperatively stimulates AR-dependent transcription. 77 Thus, the inhibition of KDM4C alone or in combination with KDM1A may be a promising therapeutic strategy to control AR activity and treat PCa.
KDM4C is also important for PCa tumor-initiating cell (TIC) self-renewal which is responsible for androgenindependence and metastatic spreading. 124 The histone lysine demethylase PHF8 responsible for H3K9me1/me2, H3K27me2, and H4K20me1 demethylation is involved in the migration and invasion of PCa, whereas KDM4C and KDM1A are vital for PCa androgen-dependent proliferation. 125 In embryonic stem (ES) cells, KDM4C expression is positively regulated by the pluripotency-specific transcription factor OCT4 by direct binding to the KDM4C intron. 126, 127 Intriguingly, the depletion of KDM4C leads to ES cell differentiation, suggesting its requirement for the maintenance of self-renewal. KDM4C also stimulates the expression of Nanog, another important stem cell-specific transcription factor.
| Breast cancer
In contrast to KDM4B, KDM4C mRNA levels are upregulated in ER-negative breast tumors compared to ERpositive tumors. 24, 128 In human breast cancer, the 9p24 amplicon contains six candidate tumor genes, including encoding KDM4C, and indeed, KDM4C is overexpressed in tumors with gene amplification. 129 However, the relationship with tumor aggression is complex. The expression levels of KDM4C are significantly higher in aggressive, basal-like breast cancer than in non-basal-like breast cancer. 24 Among invasive breast cancer patients, however, KDM4C-negative patients exhibited 2 years shorter breast cancer-specific survival and shorter time to relapse than KDM4C-positive patients. 128 KDM4C negativity is associated with tumors of more aggressive histopathological types including grade II and III, ductal type, ER-negative, and progesterone receptor-negative. In this same study, there were three times more KDM4C-negative cases than KDM4C-positive cases among HER2-positive cases. Patients with KDM4C-positive tumors show better breast cancer-specific survival rates and are more responsive to hormonal treatment and radiotherapy. KDM4C induces transformed phenotypes when overexpressed in immortalized, non-transformed mammary epithelial cells (MCF10A), whereas KDM4C knockdown inhibits tumor proliferation and metastasis. 130, 131 In addition, KDM4C controls the expression of genes important for stem cell self-renewal including NOTCH1. This result suggests that KDM4C may be related to the stem cell phenotype of breast cancer.
KDM4C is a coactivator of HIF-1α and increasing the HIF-1α transcriptional activity stimulates breast cancer progression. 130 HIF-1α-mediated KDM4C recruitment to hypoxia response elements activates the transcription of LOXL2 and L1CAM, which encode proteins that are responsible for lung metastasis as well as BNIP3, LDHA, PDK1 and SLC2A1, genes that encode proteins responsible for metabolic reprogramming, by reducing H3K9 trimethylation. 130 KDM4C expression was also strongly associated with GLUT1, LDHA, LOX, LOXL2, L1CAM, and PDK1 mRNA expression levels in human breast cancer biopsies. The depletion of KDM4C blocks breast tumor growth and spontaneous metastasis to the mice lungs after mammary fat pad injection in mice.
In addition to transcriptional activation, KDM4C regulates transcriptional repression via modulating steroid receptor coactivator-1 (SRC-1). SRC-1 facilitates the activity of ER in breast cancer cells, conferring cell survival benefits. 132 AP1 and KDM4C form a complex with SRC-1 that results in transcriptional repression.
KDM4C activity is also important in chromosome segregation of triple-negative breast cancer cell lines. 133 KDM4C is recruited to mitotic chromosomes and regulates the number of mitotic segregation errors, thereby modulating chromosomal stability. 131 KDM4C is also cleaved by the apoptotic effector protease caspase-3 within the DEVD396G motif, which causes loss of demethylating enzyme activity in the DEVD396G motif. 134 Treatment of cells with the caspase-3 activator tumor necrosis factor-α (TNF-α) increases the basal expression of the DSB repair protein γ-H2AX. Similarly, KDM4C knockdown results in the upregulation of basal γ-H2AX. The D396N polymorphism of KDM4C (rs2296067) influences the prognosis of human breast cancer by altering caspase-3-mediated cleavage and the ability of DSB repair to contribute to therapeutic resistance.
| Lung cancer
The expression of KDM4C is increased in the majority of human lung cancer tissues compared to adjacent normal tissues. 135 Moreover, KDM4C expression is higher in metastatic lung cancer tissues than non-metastatic lung cancer tissues. Multiplex fluorescence in situ hybridization (M-FISH) revealed a near-triploid karyotype with numerous structural aberrations and four to six small supernumerary marker chromosomes containing chromosome 9 in lung cancer cells. 23 Furthermore, 9p amplification was detected in both the primary tumor and another metastasis from the same patient. KDM4C overexpression promotes migration, invasion, and EM, possibly by directly regulating KDM4C expression of the ubiquitin ligase CUL4A. Moreover, interference of CUL4A reverses the enhanced migration, invasion, and EMT capacities induced by KDM4C overexpression.
The proportion of cell overexpressing KDM4C in different histologic subtypes of lung cancer is related to clinicopathologic factors and smoking habits. 136 In a lung cancer cell immunostaining study, 38% of the cell nuclei and 54% of the cytoplasmic compartments were positive for KDM4C. KDM4C expression is higher in adenocarcinoma than in SCC. Smoking reduces KDM4C expression and increases the methylation of histone H3K9 in lung cancer. Patients with greater cytoplasmic staining also tend to show shorter survival. Nonetheless, nuclear KDM4C expression is also expected to predict poor prognosis in SCC.
| Colorectal cancer
Like other KDM4s, KDM4C is overexpressed in CRC cell lines 63 and strongly associated with chromatin. KDM4C downregulation reduced both the growth and clonogenic capacity of HCT-116 colon cancer cells. 63 KDM4C activity requires the efficient expression of the growth of stimulatory proteins FRA1 and cyclin D1 as well as the survival factor BCL2. KDM4C forms CRC anchorage-independent spheres by modulating the β-catenin-dependent transcription of Jagged1 (JAG1), the notch ligand responsible for spherogenesis, in a feed-forward manner. 137 The upregulation of KDM4C expression is found in spheres of CRC cell spheres, while KDM4C knockdown eliminates the colonosphere formation. KDM4C is involved in sphere formation downstream of β-catenin. 63 KDM4C and β-catenin bind to the JAG1 promoter during the colonosphere formation. Alternatively, KDM4C knockdown reduces the expression of the JAG1 gene and downregulation of the JAG1 gene reproduces the damaged colonosphere formation. Importantly, KDM4C knockdown also inhibits β-catenin recruitment to the JAG1 promoter independent of H3K9 methylation status and slows the expression of JAG1 during sphere formation.
| Esophageal squamous cell carcinoma (ESCC)
In ESCC, non-random amplification of DNA is observed at 9p23-24 21, 138 and KDM4C was identified as the major target of amplification in ESCC cell lines, 139 while the minor amplicon contained the transcription factor, NFIB. Heterozygous mice (KDM4C +/− ) with downregulated KDM4C expression exhibited lower incidence and multiplicity of both benign and malignant tumors than wild-type mice. 140 Also, cancer volume was significantly lower in KDM4C +/− mice. Therefore, KDM4C knockdown reduces ESCC cell viability or proliferation in vivo.
KDM4C induces the transcription of MDM2 through the modulation of histone methylation on its promoter and then reduce the p53 protein expression. 141 In addition to MDM2, KDM4C activates two additional high-risk genes PPARG and NANOG) in ESCC tumors. 142 The presence of this 3-gene signature is a strong independent predictor of lower OS.
KDM4C also upregulates SOX2 expression, which is involved in human ESCC tumor-initiating cell maintenance. 143, 144 Among the TIC subgroup of ESCC patients, KDM4C expression was higher in the ALDH bri+ subpopulation. Inhibition of KDM4C reduced the ALDH bri+ population as a marker of ESCC TICs in vitro and delayed transplantation by specific targeting TICs in ALDH bri+ -derived xenografts. The intracellular expression pattern of KDM4C overlaps with SOX2 and ALDH1. In addition, ectopic expression of SOX2 restores KDM4C inhibitor-dependent ALDH bri+ TIC characteristics.
KDM4C expression in the nucleus is strongly related to tumor grades and lymph node metastasis stages. 145 Additionally, the high expression of KDM4C in the nucleus was associated with a poor survival rate in ESCC patients (5- year survival rate of 26.5% vs 43.7% of KDM4C-negative expression patients). Taken together, these data indicate that KDM4C may be a novel and effective therapeutic target for human ESCC.
| Lymphoma
Most gastric and extragastric MALT lymphoma tissue samples with immunoglobulin heavy (IGH) locus amplification show balanced translocation. 146 The IGH partner gene contains BCL6, FOXP1, MALT1 and four chromosomal regions from chromosome arms 1p, 1q, 5q, and 9p. Three partner genes have been identified in 1p (CNN3), 5q (ODZ2), and 9p (KDM4C). Most of these heterologous translocations affect the NF-κB activation pathway. The recurrent 9p24.1 aberration in lymphoma contains four potentially cancer-associated genes, JAK2, programmed death ligands 1 and 2 (PDL1/ PDL2), and KDM4C. 147 Among lymphocyte 9p24.1 changes, aberrations involving structural changes are heterogeneous, but these changes share a common breakpoint area 200 kb downstream of JAK2. The rearrangements in lymphoma mainly target the PDL locus.
Carcinogenesis of certain lymphoma subtypes involves altered gene expression profiles including the JAK/STAT pathway. 148 In lymphoma cells containing 9p24 amplified and overexpressed wild-type JAK2 protein results in activation of standard JAK/STAT signaling. STAT6 phosphorylation and IL13 production cause autocrine stimulation. Ampliconpositive lymphoma cells also possess another JAK-mediated signaling pathway involving KDM4C. Activated JAK2 migrates to the nucleus and phosphorylate histone tyrosine 41, thereby preventing the binding of HP1α at that site, while KDM4C demethylates H3K9me3 and H3K36me3. JAK2 and KDM4C act synergistically to promote heterochromatin formation and enhance the transcription of oncogenic important genes in primary mediastinal B cell and HL. 120, 149 In B cells, hypoxia induces important Hodgkin and RS cell characteristics, including PCGF2 and DUSP1 expression as well as KDM4C overexpression. 150 survival and initiate differentiation into Hodgkin and RS celllike phenotypes.
| Acute myeloid leukemia (AML)
Polycythemia vera (PV) is a clonal stem cell disorder that transforms into AML, a malignant disease characterized by excessive erythropoiesis. 151 Trisomies of chromosome 9 and 9p are the most frequent cytogenetic abnormalities together with chromosome 8 and del (20q) in both PV and idiopathic myelofibrosis. Several chromosomal abnormalities including the amplification of 9p are also detected. Amplification of 9p22 is detected at approximately p24.3, which contains JAK2, KDM4C, MLLT3, and SMARCA2. The amplification of genes in this region may play an important role in the pathogenesis of PV and AML. While KDM4C is dispensable for the survival of MLL-AF9 translocated AML, conditional Kdm4a/Kdm4b/Kdm4c tripleknockout mice cause defects in the progression of AML, suggesting that KDM4 demethylases are required for survival of the AML. 16 PRL-3 is a small carcinogenic dual-specificity phosphatase overexpressed in 50% of AML cases and predictive of poor survival rate. 152 Overexpression of PRL-3 allows cytokine-independent AML growth. AML cell growth decreases the H3K9me3 inhibitory signal and promotes expression of LEO1, a component of the RNA polymerase II-associated factor (PAF) complex, by increasing KDM4C occupancy at the LEO1 promoter. In contrast, the inhibition of LEO1 prevents PRL-3 oncogenic properties in AML. PRL-3 and LEO1 expression levels are also positively correlated in AML patients. While depletion of LEO1 causes destabilization of the PAF complex and reduces the expression of SOX2 and SOX4, potent oncogenes in myeloid transformation. The H4R3 methyltransferase PRMT1 is involved in diverse MLL and non-MLL leukemias. 152 PRMT1 is necessary but not sufficient for leukemia transformation; rather, PRMT1 oncogenicity requires simultaneous recruitment of KDM4C to mediate epigenetic transformation. The inhibition of PRMT1 and KDM4C repress transcription and the transformation capacity of MOZ-TIF2 and MLL fusions, revealing druggable therapeutic targets in AML.
| KDM4D
KDM4D lacks both the C-terminal PHD and Tudor domains and thus is only half the size of KDM4A-C. Further, it has been found only in placental mammals. 70 KDM4D also possesses a substrate specificity distinct from KDM4A-C in that demethylates H3K9me2/me3 but not H3K36me3. 2, 11 Notably, KDM4D demethylates H3K9me2 more readily than H3K9me3, despite a greater binding preference for H3K9me3. 70 In addition, while KDM4A and KDM4C form homo-and heterodimers, KDM4D only forms homodimers. 34 The involvement of KDM4D proteins has also been studied in prostate, colon, breast, and lung cancer, as well as HL. However, many fewer cancerrelated studies have been conducted on KDM4D compared to KDM4A-C and some studies all examined or focused on other KDM4s.
| Prostate cancer
Like KDM4A and KDM4C, KDM4D acts as a coactivator of the AR. In LNCaP cells, KDM4D induces PSA expression by forming a complex with AR and demethylating H3K9me3 at the PSA promoter. 34 The C-terminal region of the AR and the N-terminal of KDM4A or C-terminal of KDM4D are ligandbinding domains. KDM4A and KDM4D interact separately with AR via these different domains. KDM4D catalytic activity is required for AR coactivation. Thus, KDM4D overexpression may contribute to the constitutive activation of AR and ensuing androgen-depletion PCa.
| Colorectal cancer
Like KDM4A, KDM4D is required for CRC cell proliferation and survival. However, while KDM4A is a corepressor of p53, KDM4D is considered a p53 coactivator and tumor suppressor. KDM4D stimulates p53 transcriptional activity and target gene expression by decreasing H3K9me3 levels at the p53 promoter. 153 Expression levels of KMD4D are higher in human colorectal tumors than healthy colon and positively correlated with proliferating cell nuclear antigen expression. 17 KDM4D-knockout mice and wild-type mice treated with the KDM4D inhibitor 5-chloro-8-hydroxyquinoline develop fewer colitis-associated colorectal tumors than controls. KDM4D also binds β-catenin and induce transcription of β-catenin target genes (MYC, CCND1, MMP2, and MMP9). In addition, HDM4D upregulation promotes CRC proliferation, migration, and invasion in vitro as well as CRC tumor growth in mice.
| KDM4E and KDM4F
Bioinformatics analyses have discovered the intronless genes KDM4E and KDM4F, which otherwise resemble KDM4D. 9, 146 They are considered as pseudogenes because of their structures and absence of expression. KDM4E acts as a demethylase when ectopically expressed, 70 but its function in cancer is still unknown.
| INTERPLAY BET WEEN KDM4
AND METABOLISM
There is extensive crosstalk between epigenetic and metabolic pathways in cancer cells. Oncogene-mediated metabolic changes influence the epigenetic regulation of gene expression by altering the activities of DNA-and histonemodifying enzymes. 154, 155 These metabolic alterations could impact the availability of cofactors required for epigeneticmodifying enzymes and produce oncometabolite that activate or inhibit these enzymes, resulting in epigenomic alterations. Reciprocally, epigenetic deregulation in cancer alters the expression of metabolic genes, thereby changing the metabolome. Hence, the interplay between epigenetics and metabolism is critical for tumorigenesis and the molecular mechanism linking these biological pathways could reveal novel therapeutic targets.
| The effect of cancer-related metabolic changes in the histone demethylation activity of KDM4
Metabolites of the tricarboxylic acid (TCA) cycle affect DNA and histone demethylation by acting as cofactors or enzymatic inhibitors. The JmjC-KDM proteins are dependent oxygenases and any disturbance in the endogenous α-KG or 2-OG pool will influence the activities KDM including KDM4. KDM4 catalytic activity also appears to be regulated in other more complex ways by the cancer metabolome. 9 TCA cycle intermediates such as succinate and fumarate competitively inhibit KDM proteins 156 and cancer cells with mutations in metabolic genes may accumulate oncometabolites, such as 2-hydroxyglutarate (2-HG), succinate, and fumarate.
| 2-HG
In the TCA cycle, metabolic enzyme isocitrate dehydrogenase 1 (IDH1) and IDH2 catalyze the oxidative decarboxylation of isocitrate to α-KG using nicotinamide adenine dinucleotide phosphate (NADP) as a cofactor. 157 Mutations in IDH1/2 have been found in AML, 158 angioimmunoblastic T-cell lymphoma, 159 chondrosarcomas, and low-grade gliomas. 160, 161 Cancer-related mutations in IDH1/2 appear frequently at substrate-binding sites (eg, IDH1 at R132; IDH2 at R140/172). Overexpression of mutant IDH1 or 2 promotes cancer cell proliferation and colony formation and blocks cellular differentiation in vitro. [162] [163] [164] While wide-type IDH1/2 convert isocitrate to α-KG, mutant IDH1/2 convert α-KG to 2-HG in some cancer cell types. 165 Owing to structural similarity, 2-HG acts as a competitive antagonist for α-KG. 166 Mutant IDH1/2 results in an increased level of 2-HG and an increase in histone methylation. 167 2-Hydroxyglutarate also inhibits the catalytic activity of other α-KG-dependent oxygenases, including ten-eleven translocations (TETs) and PHD2 as well as KDMs. 168 2-HG has been demonstrated to strongly inhibit several KDMs: KDM4A, KDM4C, KDM2A, 169 and KDM7A. 164, 166 In U87MG glioblastoma cells, 2-HG treatment or overexpression of mutant IDH1 elevates the dimethylation of H3K9, H3K27 and H3K79 and the trimethylation of H3K4. 166 Among these histone methylation markers, H3K9me3 is strongly associated with pluripotency and the inhibition of differentiation. 164 Oligodendroglioma patients with mutant IDH1 also possess higher H3K9me3 levels than patients with wild-type IDH1/2. 170 Inhibition of mutant IDH1 in glioma and IDH2 in leukemia strongly induces cellular differentiation. 171, 172 Conversely, transfection of 2-HG-producing mutant IDH into immortalized astrocytes prevents histone demethylation, which is necessary for lineage-specific progenitor cells to differentiate into terminally differentiated cells. 164 Indeed, increased H3K9 methylation is normally observed as cells pass through the steps of differentiation. In addition, 2-HG-inhibitable KDM4C is induced during adipocyte differentiation and knockdown of KDM4C is sufficient to inhibit differentiation. These findings demonstrate that 2-HG can block histone demethylation via KDM4C inhibition and that reduced histone demethylation can prevent the differentiation of non-transformed cells. Moreover, small-molecule inhibitors of IDH1 and IDH2 (AG-120 and AG-211, respectively) are currently being tested in phase II clinical trials for the treatment of AML patients with the respective IDH1 or IDH2 mutations.
| Succinate and fumarate
In addition to IDH, other TCA cycle enzymes such as succinate dehydrogenase (SDH) and fumarate hydratase (FH) are mutated in various cancers. SDH mutations are found in gastrointestinal stromal tumors, renal cell carcinoma, paraganglioma, and pheochromocytoma, 173-175 while FH mutations have been observed in hereditary leiomyomatosis and renal cell cancer. 176 SDH catalyzes the oxidation of succinate to fumarate and of fumarate and FH the oxidation of malate. Thus, loss-of-function mutations in SDH and FH cause the accumulation of succinate and fumarate, respectively.
By producing inhibitory cofactors of KDMs, FH and SDH are driver genes and modulate epigenetic alterations. 177 of TETs and KDMs, including KDM4A, KDM4D, and KDM2A. 156 Sdhb knockout mice show increased histone methylation levels at H3K9 and H3K27. 178 In Sdhb knockout cells, epigenetic dysregulation induces the downregulation of genes associated with metastasis suppression. Consistent with these findings, a deregulated epigenetic landscape is frequently found in mutant SDH or FH tumors. Moreover, paraganglioma patients with mutant SDH or FH have a far worse prognosis. 178 Thus, genetic mutations in SDH and SH leading to accumulation of succinate and fumarate, respectively, trigger tumorigenesis via epigenetic dysregulations.
| KDMINHIBITORS AS NOVEL EPIGENETIC CANCER AGENTS
There is growing evidence to suggest that enhanced KDM4 catalytic activity and expression contribute to carcinogenesis or tumor progression. Indeed, global alterations in histone methylation are associated with poor prognosis, patient relapse, and chemoresistance. KDM4 proteins can act as an oncoprotein and so are potential therapeutic targets for cancer treatment. KDM inhibitors can be divided into four classes according to their mechanisms. 179 The first class are α-KG or 2-OG cofactor mimics and the second class are metal cofactor disruptors that inhibit KDM activity by preventing iron and zinc from acting as cofactors. The third class is the histone substrate competitive inhibitors. The third class is the histone substrate competitive inhibitors, which include methyllysine histone substrate mimics. 180 The crystal structures for α-KG oxygenases such as KDM4A 181 have revealed highly conserved Fe(II)-and α-KG-binding sites. 182, 183 However, differences in Fe(II)-and α-KG-binding sites among KDMs may be utilized for the development of selective inhibitors. In addition, a novel inhibitor that targets KDM through non-cofactor and non-substrate interactions has been developed. 184 To date, however, progress in the development of potent selective inhibitors for the KDM4s has been very slow. Furthermore, potent and specific inhibitors for other KDM enzymes have not been identified due to the lack of structural information.
| α-KG and 2-OG cofactor mimics: metal-chelated inhibitors
Most KDM inhibitors are of the first class, broad-spectrum α-KG or 2-OG cofactor inhibitors. These inhibitors competitively bind Fe(II) molecules at the catalytic site and suppress all key regions of the KDM protein, 185 α-KG is required for the demethylation of all JmjC-containing demethylases. Therefore, one possible inhibitory strategy is the development of α-KG/2-OG analogs. These include the oxayly acid-derivative N-oxalylglycine (NOG), which was identified as a PHD2 inhibitor for HIF and a weak inhibitor of KDM4A and KDM4C. 10 The cocrystal structure showed that the oxalyl group of NOG binds to the Fe(II), while the carboxyl group of glycine forms hydrogen bonds with Lys241 and Tyr177 of KDM4A. 181 Although some 2-OG analogs have been demonstrated to be potent inhibitors, these compounds possess poor cell penetration due to their large hydrophilic structures. 3
| Hydroxamic acid-based inhibitors
Screens for inhibitors JmjC-KDMs, using KDM4E have identified 2-OG analogs hydroxamate as potential KDM4 inhibitors. 186 The hydroxamate-based compounds exhibit good selectivity for the KDM4 family. The hydroxamate analog NCDM32 is a 500-fold more potent inhibitor of KDM4C than NOG. Basal breast cancer cells treated with the NCDM-32B show reduced anchorage-independent growth and cell viability. 45, 187, 188 Another hydroxamate analog is a potent and selective KDM4C inhibitor that exhibits 500-fold greater inhibitory activity and 100-fold greater selectivity than lead compound NOG. 13, 188 A pan-HDACi SAHA with a metal-chelating moiety also shows mild inhibitory activity against KDM4s. 186 The hydroxamate group of SAHA replaces the oxalyl group of NOG to bind the Fe(II) in KDM4s. Although many hydroxamatebased inhibitors have been studied, a KDM4-selective inhibitor with sufficient selectivity and efficacy for clinical applications has not yet been reported.
| Pyridine dicarboxylates (PDCA)based inhibitors
Although the physicochemical features and selectivity of PDCA derivatives for KDMs are not yet satisfactory, these compounds are more rigid 2-OG analogs than NOG and hydroxamate-based compounds. Some PDCA (eg, 2,4-PDCA) and bipyridine derivatives containing both 2,2-bipyridine and a 4-carboxylate selectively inhibit KDM4E over PHD2 within the submicromolar to the micromolar range. 186, [189] [190] [191] The metal binding pyridine moiety is regarded as a potential KDM4A inhibitor scaffolds. 186 A much larger and accessible subpocket is found within the KDM4 active site than in other oxygenases based on the KDM4A; NOG crystal structure. 181, 192 This subpocket extends into the groove where substrates engage. Thus, for selective inhibition of KDM4 protein, N-oxalyl-D-phenylalanine derivatives occupying this subpocket have been developed. More detail information about pyridine-based inhibitors is summarized by Lin et al. 193 
| Hydroxyquinoline (HQ)-
Based Inhibitors
Compounds structurally unrelated to α-KG can also bind and inhibit KDM4 catalytic sites. 8-HQ derivatives inhibit H3K9 demethylation in HeLa cells by binding to the active site Fe(II). 194 The 8-HQ derivative SD70 was identified as a KDM4C-specific inhibitor through the Chem-seq method and phenotypic screening. 195 SD70 inhibits prostate cancer cell growth in vitro (IC 50 = 5-10 mM) and in vivo (10 mg/kg/day), but the in vitro selectivity profile has not been tested. Related compounds, such as the 6-substituted quinolin-8-ol analogs, ML324 effectively inhibits KDM4A-mediated early viral gene replication in herpesvirus-infected cells. 196, 197 In addition, ML324 exhibits submicromolar inhibition against KDM4E in vitro (IC 50 = 920 nM). 198 
| Metal cofactor disruptors
Disruption of iron and zinc cofactor binding also inhibits KDM catalytic activity and can be achieved using both non-iron metals and organic molecules. Non-iron metals including nickel incapacitate the catalytic activity of KDM4A and KDM4C by occupying the iron-binding pocket. 199 As revealed by bioinformatics and structural analyses, the Zn(II)-Cys3-His-binding site is located within the KDM4A catalytic domain but is not present in other α-KG-dependent oxygenases. 189 Zn 2+ ions, required for catalytic activity in KDM4A, can be locally released through the binding of Zn-ejecting compounds such as disulfiram (IC 50 = 3.3 μM) and ebselen (IC 50 = 10.6 μM). In addition, 2-(1H-tetrazol-5-yl)acetohydrazide with an iron-chelating moiety has a relatively low molecular weight, low complexity, and high affinity for the KDM4A metal-binding site, with an IC 50 value of 46.6 μM in an FDH-coupled assay and 2.4 μM by antibody-based analysis. 200 These metal cofactor disruptors may provide other inhibitory mechanisms that can be used to selectively target KDM4. However, numerous proteins contain zinc ion binding sites so the selectivity of Zn-ejecting compounds for KDM4A requires further study.
| Histone substrate competitive inhibitors
Truncated or modified substrate peptides have also been developed as substrate mimic inhibitors. For example, the truncated H3K9me3 substrate H3 [7] [8] [9] [10] [11] [12] [13] [14] Kme3 peptide showed the best affinity KDM4A among KDM4s, even better than some longer peptides. 201 Also, several methyllysine histone substrate mimics have been designed and examined. [202] [203] [204] [205] Tudor domain inhibitors competitively bind to H3K4me3 in the methyllysine-binding pocket and moderately suppress KDM4A activity in vitro. 191, 205 In contrast, the MS-275 derivative was designed and synthesized as a combined methyllysine-containing substrate and cofactor mimetic (α-KG mimic). 202 Two inhibitors linking NOG with substrate peptides exhibit better inhibitory activities and selectivity for KDM4A and KDM4D compared to other KDM4s. 204 The Jumonji family-specific inhibitor JIB-04 inhibits the catalytic activity of KDM4A, KDM4B, and KDM4E effectively in vitro and in vivo. 191 Importantly, JIB-04 reduces tumor burden and extends cancer survival in mice in vivo. While the molecular mechanism for inhibition is unclear, it is known that JIB-04 does not influence the function of other α-KG-dependent enzymes and the transcriptional growth program in normal cells. 206 JIB-04 is now known to disrupt the linkage O 2 docking, inhibit translation initiation, and improve the mTOR inhibitor sensitivity of KDM4A. 207 NSC636819 significantly suppresses histone demethylase activity at H3K9me3 and triggers the apoptosis in PCa cells. 82 The compound targets KDM4A and KDM4B with IC 50 values of 6.4 and 9.3 μM, respectively, and provides a new structural framework based on the selective peptidebinding region.
Co-2-OG and -histone substrate mimics have also been reported in which a chlorobenzyl piperidine group is incorporated into the substrate methylated lysine side subpocket. These mimics display high-affinity inhibition of KDM4B and KDM4A (IC 50 = 17 nM and 80 nM, respectively). 208 Also, the replacement of the 4-carboxylate group with a pyrido [3,4-d] pyrimidin-4(3H)-one group enhances cellular permeability. 209 Additionally, some 3-amino-4-pyridine carboxylate derivatives have been identified as KDM4 inhibitors. 193 More recent work with cyclic peptides targeting KDM4 has revealed that high selectivity can be accomplished via substrate competitive inhibitors. Crystal structural and biochemical analyses of KDM4A with its inhibitor indicate that macrocyclic peptide CP2 competes with the histone in the substrate-binding pocket despite different binding mechanisms. 210 The potent IC 50 values of KDM4A-C are 42 nM for KDM4A, 33 nM for KDM4B, and 39 nM for KDM4C, according to a luminescence-based AlphaScreen assay. CP2 shows higher potency against KDM4A-C compared to KDM4D and E (IC 50 = 270 nM vs 9200 nM for KDM4D and KDM4E, respectively). Substitution of the active site-binding arginine of CP2 with N-ε-trimethyl-lysine or methylated arginine yields cyclic peptide substrates, suggesting that KDM4s may act on non-histone substrates. Further in vivo studies of cyclic peptides are necessary. 
| Cyclic peptides
KDM4A-D proteins are highly conserved at the active sites. Most inhibitors target either the cofactor-or substrate-binding sites of these KDM enzymes, resulting in lower selectivity and off-target effects. To overcome this caveat, it explored to develop new inhibitors targeting KDM4 through substrate-and cofactor-independent interactions have been examined. Two cyclic peptides were identified and developed as KDM4C-specific inhibitors through the screening of peptide-based phage display. 184 Cyclic peptides bind in allosteric sites and less conserved regions of KDM4C located on the surface remote from the active site. These preliminary results may ultimately contribute to the identification of new binding sites for KDM4C-selective inhibitors. of many JmjC-KDM-associated PHD-fingers, some seem to functions in targeting JmjC-KDMs to certain histone modification marks (eg, in KDM7A/B). 211 Recently, smallmolecule inhibitors targeting the third PHD-finger of KDM5A (KDM5A-PHD3) were found by applying a HaloTag assay to screen for molecules that displaced histone H3K4me3 binding to PHD3. 211 However, KDM4 inhibitors targeting non-catalytic domains have not yet been identified.
| Non
| CONCLUSIONS
KDM4 demethylases are ubiquitous regulators of chromatin structure and gene expression through H3K9 and H3K36 demethylation. Global dysregulation of KMT1s and KDM4s contributes to the progression of cancer. KDM4 subfamily members are overexpressed in numerous tumor types and there is now compelling evidence that this overexpression promotes tumorigenesis and predicts poor prognosis and relapses. Elevated KDM4 protein expression promotes cancer cell proliferation survival, migration, and metastasis as well as tumor angiogenesis and resistance to DNA damage ( Figure 3) . Thus, KDM4s are promising targets for cancer therapy.
Despite extensive knowledge on KDM4 functions, it is still often unclear how KDM4 proteins are recruited to specific genomic loci, the specific genetic programs activated or suppressed by KDM4 overexpression and associated epigenetic modifications, and how these genetic and epigenetic changes contribute to carcinogenesis. Further, it is still not possible to control histone demethylation at specific downstream target sites.
However, given the reversibility of epigenetic changes, KDM4 proteins are potential for anticancer drugs. However, the development of potent and selective KDM4 inhibitors has proven challenging as closely related KDM proteins may be targets and non-targets within the same cell. Most of the inhibitors studied to date are active against non-target proteins associated with KDM4. Most inhibitors are cofactors or substrate mimics with poorly understood mechanisms of action on specific KDM4s. Also, many KDMs share cofactors, so such mimics are by definition nonselective. These issues have prevented KDM inhibitors from progressing beyond basic research to clinical research and medical applications. Although these studies are at a relatively early stage, the non-catalytic domain may be more selective potential therapeutic targets. However, screening for such compounds requires the development of a method to measure KDM activity accurately in situ. Inhibitors identified to date have low specificity and are unlikely to be commercially available. Thereby, further studies on more potential inhibitors that can selectively inhibit specific KDM4 are needed.
